Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
about
Interaction with PI3-kinase contributes to the cytotoxic activity of apoptinDual modification of BMAL1 by SUMO2/3 and ubiquitin promotes circadian activation of the CLOCK/BMAL1 complexBax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell deathIdentification of the non-structural influenza A viral protein NS1A as a bona fide target of the Small Ubiquitin-like MOdifier by the use of dicistronic expression constructsGallus Heat shock cognate protein 70, a novel binding partner of ApoptinNonviral gene therapy in vivo with PAM-RG4/apoptin as a potential brain tumor therapeuticSUMOylation affects the interferon blocking activity of the influenza A nonstructural protein NS1 without affecting its stability or cellular localization.Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity.Secretory Transactivating Transcription-apoptin fusion protein induces apoptosis in hepatocellular carcinoma HepG2 cells.Activation of the Chicken Anemia Virus Apoptin Protein by Chk1/2 Phosphorylation Is Required for Apoptotic Activity and Efficient Viral ReplicationViral genes as oncolytic agents for cancer therapy.Apoptin interacts with and regulates the activity of protein kinase C beta in cancer cells.A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis.Marek’s disease virus oncoprotein Meq physically interacts with the chicken infectious anemia virus-encoded apoptotic protein apoptin.
P2860
Q24302220-6DE02B76-1BB4-49DD-B7E4-DBF6D2D06511Q24646355-827CE34D-858D-4488-95C7-F3721AAD63BFQ30480587-90624770-A2FD-457B-805C-4D055F0F46D7Q33711733-6D9E1E1F-2BA3-47B6-BD4B-B97795F89CAAQ35111448-A1D1281C-AA1C-4E5A-AEF5-31A27EEE71D7Q36755625-973FA329-82C7-4D81-A2F9-5747A9FCCBA5Q36827413-C19FCD1A-CDB2-4FF4-8171-12AC387720C4Q37099933-C972B1CF-DD77-47F1-9AB8-72459F29FA9FQ37284800-5B01A26D-8ED3-437E-BE9D-532FBCCBD879Q37300406-C4D595B1-F0B2-4141-B274-1CD0E9D6A723Q38269469-321691BA-5521-4459-9F7C-3146DED4F652Q39023018-570E73C5-9B92-4ED0-8F9C-A5C6C5D69F87Q40083895-34A71BC4-DF67-4C37-AE5E-F5473007ABEDQ55493565-367F89EA-F81D-4491-87B7-267D8CE20CA1
P2860
Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Apoptin is modified by SUMO co ...... ukemia protein nuclear bodies.
@en
type
label
Apoptin is modified by SUMO co ...... ukemia protein nuclear bodies.
@en
prefLabel
Apoptin is modified by SUMO co ...... ukemia protein nuclear bodies.
@en
P2093
P2860
P356
P1433
P1476
Apoptin is modified by SUMO co ...... eukemia protein nuclear bodies
@en
P2093
K Schulze-Osthoff
T G Hofmann
P2860
P2888
P304
P356
10.1038/SJ.ONC.1209923
P407
P577
2006-08-21T00:00:00Z
P5875
P6179
1010749672